Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Crossref DOI link: https://doi.org/10.1007/s12325-019-01187-y
Published Online: 2019-12-20
Published Print: 2020-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamamoto, Nobuyuki
Mera, Takeshi
Märten, Angela
Hochmair, Maximilian J.
Funding for this research was provided by:
Boehringer Ingelheim
Text and Data Mining valid from 2019-12-20
Version of Record valid from 2019-12-20
Article History
Received: 1 November 2019
First Online: 20 December 2019